about
Microbial translocation is a cause of systemic immune activation in chronic HIV infectionHepatitis C Virus-Specific T-Cell Gamma Interferon and Proliferative Responses Are More Common in Perihepatic Lymph Nodes than in Peripheral Blood or LiverDifferential Effects of Hepatitis C Virus JFH1 on Human Myeloid and Plasmacytoid Dendritic CellsTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadAssociation between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineToll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis.Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activationHIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production.Effect of early versus deferred antiretroviral therapy for HIV on survival.Late presentation for human immunodeficiency virus care in the United States and Canada.Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaPretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohortMissing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells.Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individualsAccessory cell dependent NK cell mediated PBMC IFN-gamma production is defective in HIV infection.In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects.Interferon-alpha administration enhances CD8+ T cell activation in HIV infectionInflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North AmericaReduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infectionIncomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.Effect of Nadir CD4+ T cell count on clinical measures of periodontal disease in HIV+ adults before and during immune reconstitution on HAART.Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.Identification of occult Fusobacterium nucleatum central nervous system infection by use of PCR-electrospray ionization mass spectrometry.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successRisk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screeningDeterminants of protection among HIV‐exposed seronegative persons: an overview.Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.
P50
Q22251054-0A43682C-F209-4442-9E27-3D05A0DE2BB8Q27487339-622733A6-6444-4BB0-A44F-BFF17C609962Q27488392-2BBF6728-4517-4785-A675-D20254C8920CQ28478656-15F74BC3-4BF7-405A-8897-7CAA986C031FQ28535233-8A12C2FE-2003-4189-A4EC-1D1D4561B6C4Q31146636-F0DFFBE4-5565-4B7F-A2C2-A92C0BE8ACFBQ33326642-4E04FE1E-D230-4DD3-8C79-B04F6080D96DQ33594461-765B9832-151A-4B35-B351-E2F26A6D90F2Q33597485-8F624479-2682-458A-9F69-506ED6187EDCQ33598231-C4916584-FB71-4750-9432-6C925F6E9EC7Q33648774-AFC6342D-C6A9-49D7-B344-602C86577622Q33707350-A7535803-F5FA-4F62-B00F-A7513CD6DB11Q33789114-D54BD495-29D0-4BD9-BA33-5F576291CC85Q33823556-EC440119-08D1-4ECD-9D72-B087C96FF915Q33853922-4CD89228-7D56-49D5-A5FE-917714E4F49EQ33862741-5C88B586-5335-439B-92E6-CCC61614A792Q33917964-721E08B9-9C0E-4948-9C6B-15D48421B35CQ33981074-A054154D-2ADE-4AFF-ADCF-1092BD973637Q33999813-B6F1FD61-FF4E-47DE-BC03-B8A112636B5AQ34017771-0871FC18-4D12-47AC-89AB-B8EB7997E4F4Q34020111-791C4EF9-C053-4531-B9F8-B7720473D1E3Q34020126-5E9D9471-2496-4D91-B6FD-57098D8EE76DQ34050143-12BC7660-9462-491B-8B74-0E20DBD68E32Q34143557-47F87448-186C-4A18-8D87-9DD25D601AACQ34145979-EC317E8C-1066-415C-83E8-74CAD721777BQ34229695-BA4F50DE-D637-4CE5-857D-D2C70641065AQ34315572-F1F1D77E-D6A9-4161-9A30-5D5E9131E4C1Q34315579-ACA7BE5D-5BB9-4218-9804-A8CD1644FF74Q34499000-B104EFF6-7A8F-42F8-BEAB-F8CD114418ADQ34598849-28BB96B4-290D-4C32-9784-9188ABBD5700Q34635523-2D59348D-FA74-4059-8BDF-FA2EAA27D780Q34772857-49D01166-B81C-4F10-8A72-CA701F52C69DQ34937231-CC004375-0F41-49F3-B1E8-9CF5133A8EDBQ35023018-183D30E4-AE38-4DBF-84DA-421E9F251EBBQ35029328-5015C677-6606-4A08-B675-F7B6F4D67064Q35035854-60827C53-6CD7-432E-BD3E-6DA1D536C8DAQ35043700-78C490C3-5EE4-4857-B61C-65727CD0E14FQ35167106-BB13A553-1C1A-4750-91BE-AAD26ADF5188Q35252566-5985D60F-4CBB-459B-A1A4-BA045BD2F6F6Q35295887-2A27A861-C7D0-40AE-B93B-7B74D7D5AF33
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Benigno Rodriguez
@ast
Benigno Rodriguez
@en
Benigno Rodriguez
@es
Benigno Rodriguez
@nl
Benigno Rodriguez
@sl
type
label
Benigno Rodriguez
@ast
Benigno Rodriguez
@en
Benigno Rodriguez
@es
Benigno Rodriguez
@nl
Benigno Rodriguez
@sl
prefLabel
Benigno Rodriguez
@ast
Benigno Rodriguez
@en
Benigno Rodriguez
@es
Benigno Rodriguez
@nl
Benigno Rodriguez
@sl
P1053
C-3365-2009
P106
P1153
7102299542
P21
P31
P3829
P496
0000-0001-9736-7957